Monday, July 26, 2021

BDR Pharma inks licensing pact with Eli Lilly for Covid-19 treatment drug – ET HealthWorld


Drug firm, BDR Pharma on Wednesday said it has inked a licensing pact with Eli Lilly and Company for the manufacturing and distribution of Baricitinib for the treatment of Covid-19 in India. The company said it has entered into a royalty-free, limited and non-exclusive voluntary licensing agreement with Eli Lilly and Company.

Baricitinib has received restricted emergency use approval, for use in combination with Remdesivir, for treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults and pediatric patients of two years age or older, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.

Eli Lilly has received permission for the drug for restricted emergency use from the Central Drugs Standard Control Organization, a division of the Ministry of Health.

Baricitinib is an oral medication currently registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs.

“We hope this collaboration will address more unmet medical needs by broadening and deepening the discovery and development of Covid-19 treatments options,” BDR Pharmaceuticals Chairman Dharmesh Shah said in a statement.

BDR has applied for restricted emergency use approval with the Drug Controller General of India (DCGI) for baricitinib for Covid-19 in India.

Lilly has already announced seven voluntary license agreements with major local generic drug manufacturers in India for the production of the same.

“Lilly is committed to supporting India in this healthcare challenge through our innovative and effective portfolio of breakthrough medicines. We are swiftly working to ensure high quality manufacturing and equitable access of Baricitinib for Covid-19 in India. We will continue to explore other possible initiatives to support patients and the healthcare system in India,” Lilly India Managing Director (India Subcontinent) Luca Visini said.





Source link

Stay Connected

1,605FansLike
11,000FollowersFollow
342FollowersFollow
775FollowersFollow

Latest Articles

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...

Telangana caps Covid treatment charges in private hospitals

Hyderabad: The government of Telangana on Wednesday issued orders fixing treatment and investigation charges for Covid-19 in private hospitals.The state government, which had capped...